ArticleInfectious diseases and therapy2026
Synchronous anal HPV Infection in Patients with HPV-Related Gynaecological Diseases: A Prospective Study.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06574087 (Determining the Frequency of Occurrence and Defining the Most Appropriate Screening Test for Anal Intraepithelial Neoplasia), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Determining the Frequency of Occurrence and Defining the Most Appropriate Screening Test for Anal Intraepithelial Neoplasia (AIN) in Patients With Human Papillomavirus (HPV) Related Gynecological Diseases.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
introductionPatients with human papillomavirus-related gynaecological diseases (HPV-RGD) are at risk of synchronous HPV infections in other regions, including the anal canal. The primary objective of this work was to examine the prevalence of anal HPV in patients treated for HPV-RGD. Secondary objectives were to test HPV type distribution and the risk of anal infection depending on the HPV-RGD localization.
methodsA prospective study was conducted with two groups: the research group, histologically confirmed HPV-RGD, and the control group, gynaecological diseases not related to HPV (all human immunodeficiency virus (HIV) negative). The swabs for HPV genotyping and liquid cytology (Anyplex II HPV HR Detection test) were collected from the anal canal (both groups) and the area of gynaecological disease (research group).
resultsThe prevalence of anal HPV infection in the research group (n = 130) was significantly higher than in the control group (n = 100) (64.62% vs. 11%, p < 0.05). All patients with vulva cancer (n = 7) and vaginal precancer (n = 6) exhibited anal HPV infection (p < 0.05). The risk of anal infection in patients with cervical cancer and precancer was 64% and 61.9%, respectively (both p < 0.05). The most common HPV types detected in the anus were 16 (53.6% of all anal HPV-positives), followed by 31 (17.9%) and 51 (14.3%). In 84.5% of cases, the same HPV type was present in the anus and gynaecological organ.
conclusionsPatients with HPV-RGD, HIV-negative, are at risk for synchronous anal HPV infection, with type 16 being the most common. Further research is warranted to define the clinical significance of this finding and the introduction of anal cancer screening among patients with HPV-RGD.
trial registrationClinicalTrials.gov identifier, NCT06574087.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.